How has been the historical performance of Natco Pharma?

Answer:The historical performance of Natco Pharma shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025. Breakdown: Natco Pharma's net sales have steadily increased from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025. Operating profit (PBDIT) also saw substantial growth, moving from 690.00 Cr in March 2020 to 2,550.50 Cr in March 2025, with an operating profit margin that improved from 30.42% to 49.58% over the same period. Profit before tax increased from 568.70 Cr in March 2020 to 2,291.40 Cr in March 2025, while profit after tax rose from 458.10 Cr to 1,883.40 Cr, indicating a strong upward trend in profitability. The company's total assets grew from 4,587.80 Cr in March 2020 to 8,580.70 Cr in March 2025, and total liabilities increased from 4,587.80 Cr to 8,580.70 Cr, reflecting the company's expansion. Cash flow from operating activities improved significantly, reaching 1,696.00 Cr in March 2025, compared to 417.00 Cr in March 2020. Overall, Natco Pharma has demonstrated impressive growth in sales, profits, and cash flow, positioning itself strongly in the pharmaceutical sector.